Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus PRED G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus PRED G.
EYSUVIS vs PRED-G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Prednisolone acetate is a glucocorticoid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; gentamicin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to 30S ribosomal subunit.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
1 drop of the ophthalmic suspension (containing prednisolone acetate 1% and gentamicin sulfate 0.3%) into the affected eye(s) every 2-4 hours during the day, then taper as clinical signs improve. For severe disease, 1 drop every hour initially.
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
The terminal elimination half-life of gentamicin (the active component) is approximately 2–3 hours in adults with normal renal function. In neonates, half-life is prolonged to 5–11 hours. The immunosuppressive component (prednisolone) has a half-life of 2–4 hours.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Renal excretion accounts for approximately 70% of elimination, with the remainder as unchanged drug in feces (20%) and biliary excretion (10%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination